on August 13, 2007
Published online before print August 13, 2007, doi: 10.1161/CIRCULATIONAHA.106.645614
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on July 19, 2006
From the Department of Internal Medicine, Divisions of Hypertension (J.M.M., N.S., R.G.V., L.S.S.) and Endocrinology (I.L., I.Z., P.R.), Touchstone Center for Diabetes Research (R.U.), and the Department of Radiology (T.T., L.S.S.), University of Texas Southwestern Medical Center; Veterans Affairs Medical Center (R.U.); and Institute for Exercise and Environmental Medicine (B.D.L.), Presbyterian Hospital; all in Dallas, Tex. * To whom correspondence should be addressed. E-mail: lidia.szczepaniak{at}utsouthwestern.edu.
Background—The risk of heart failure in type 2 diabetes mellitus is greater than can be accounted for by hypertension and coronary artery disease. Rodent studies indicate that in obesity and type 2 diabetes mellitus, lipid overstorage in cardiac myocytes produces lipotoxic intermediates that cause apoptosis, which leads to heart failure. In humans with diabetes mellitus, cardiac steatosis previously has been demonstrated in explanted hearts of patients with end-stage nonischemic cardiomyopathy. Whether cardiac steatosis precedes the onset of cardiomyopathy in individuals with impaired glucose tolerance or in patients with type 2 diabetes mellitus is unknown. Methods and Results—To represent the progressive stages in the natural history of type 2 diabetes mellitus, we stratified 134 individuals (age 45±12 years) into 1 of 4 groups: (1) lean normoglycemic (lean), (2) overweight and obese normoglycemic (obese), (3) impaired glucose tolerance, and (4) type 2 diabetes mellitus. Localized 1H magnetic resonance spectroscopy and cardiac magnetic resonance imaging were used to quantify myocardial triglyceride content and left ventricular function, respectively. Compared with lean subjects, myocardial triglyceride content was 2.3-fold higher in those with impaired glucose tolerance and 2.1-fold higher in those with type 2 diabetes mellitus (P<0.05). Left ventricular ejection fraction was normal and comparable across all groups. Conclusions—In humans, impaired glucose tolerance is accompanied by cardiac steatosis, which precedes the onset of type 2 diabetes mellitus and left ventricular systolic dysfunction. Thus, lipid overstorage in human cardiac myocytes is an early manifestation in the pathogenesis of type 2 diabetes mellitus and is evident in the absence of heart failure.
Accepted on June 15, 2007
Cardiac Steatosis in Diabetes Mellitus. A 1H-Magnetic Resonance Spectroscopy Study
Jonathan M. McGavock PhD,
Key words: magnetic resonance spectroscopy • obesity • metabolism
This article has been cited by other articles:
 |
|
 |
|
  E. J. Anderson, A. P. Kypson, E. Rodriguez, C. A. Anderson, E. J. Lehr, and P. D. Neufer Substrate-specific derangements in mitochondrial metabolism and redox balance in the atrium of the type 2 diabetic human heart. J. Am. Coll. Cardiol., November 10, 2009; 54(20): 1891 - 1898. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Marfella, C. Di Filippo, M. Portoghese, M. Barbieri, F. Ferraraccio, M. Siniscalchi, F. Cacciapuoti, F. Rossi, M. D'Amico, and G. Paolisso Myocardial lipid accumulation in patients with pressure-overloaded heart and metabolic syndrome J. Lipid Res., November 1, 2009; 50(11): 2314 - 2323. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. C. Schulze Myocardial lipid accumulation and lipotoxicity in heart failure J. Lipid Res., November 1, 2009; 50(11): 2137 - 2138. [Full Text] [PDF]
|
|
|
|
 |
|
 P. Iozzo, R. Lautamaki, R. Borra, H.-R. Lehto, M. Bucci, A. Viljanen, J. Parkka, V. Lepomaki, R. Maggio, R. Parkkola, et al. Contribution of Glucose Tolerance and Gender to Cardiac Adiposity J. Clin. Endocrinol. Metab., November 1, 2009; 94(11): 4472 - 4482. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. H. Opie and J. Knuuti The adrenergic-Fatty Acid load in heart failure. J. Am. Coll. Cardiol., October 27, 2009; 54(18): 1637 - 1646. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Lingvay, V. Esser, J. L. Legendre, A. L. Price, K. M. Wertz, B. Adams-Huet, S. Zhang, R. H. Unger, and L. S. Szczepaniak Noninvasive Quantification of Pancreatic Fat in Humans J. Clin. Endocrinol. Metab., October 1, 2009; 94(10): 4070 - 4076. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Bugger and E. D. Abel Rodent models of diabetic cardiomyopathy Dis. Model. Mech., September 1, 2009; 2(9-10): 454 - 466. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. W. Rabkin and P. Lodha Stearic acid-induced cardiac lipotoxicity is independent of cellular lipid and is mitigated by the fatty acids oleic and capric acid but not by the PPAR agonist troglitazone Exp Physiol, August 1, 2009; 94(8): 877 - 887. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. W. van der Meer, L. J. Rijzewijk, H. W.A.M. de Jong, H. J. Lamb, M. Lubberink, J. A. Romijn, J. J. Bax, A. de Roos, O. Kamp, W. J. Paulus, et al. Pioglitazone Improves Cardiac Function and Alters Myocardial Substrate Metabolism Without Affecting Cardiac Triglyceride Accumulation and High-Energy Phosphate Metabolism in Patients With Well-Controlled Type 2 Diabetes Mellitus Circulation, April 21, 2009; 119(15): 2069 - 2077. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. K Mcguire, R. See, S. M Abdullah, P. G Snell, J. M Mcgavock, C. R Ayers, and L. S Szczepaniak The effect of rosiglitazone on integrated cardiovascular performance, cardiac structure, function and myocardial triglyceride: trial design and rationale Diabetes and Vascular Disease Research, January 1, 2009; 6(1): 43 - 50. [Abstract] [PDF]
|
|
|
|
 |
|
 L. R. Loehr, W. D. Rosamond, C. Poole, A. Marie McNeill, P. P. Chang, A. R. Folsom, L. E. Chambless, and G. Heiss Association of Multiple Anthropometrics of Overweight and Obesity With Incident Heart Failure: The Atherosclerosis Risk in Communities Study Circ Heart Fail, January 1, 2009; 2(1): 18 - 24. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. E. Hudsmith and S. Neubauer Magnetic resonance spectroscopy in myocardial disease. J. Am. Coll. Cardiol. Img., January 1, 2009; 2(1): 87 - 96. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. J. Rijzewijk, R. W. van der Meer, J. W.A. Smit, M. Diamant, J. J. Bax, S. Hammer, J. A. Romijn, A. de Roos, and H. J. Lamb Myocardial Steatosis Is an Independent Predictor of Diastolic Dysfunction in Type 2 Diabetes Mellitus. J. Am. Coll. Cardiol., November 25, 2008; 52(22): 1793 - 1799. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. B. Lindsey and S. P. Marso Steatosis and Diastolic Dysfunction The Skinny on Myocardial Fat. J. Am. Coll. Cardiol., November 25, 2008; 52(22): 1800 - 1802. [Full Text] [PDF]
|
|
|
|
|
|
T.-S. Park, Y. Hu, H.-L. Noh, K. Drosatos, K. Okajima, J. Buchanan, J. Tuinei, S. Homma, X.-C. Jiang, E. D. Abel, et al. Ceramide is a cardiotoxin in lipotoxic cardiomyopathy J. Lipid Res., October 1, 2008; 49(10): 2101 - 2112. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Puthanveetil, F. Wang, G. Kewalramani, M. S. Kim, E. Hosseini-Beheshti, N. Ng, W. Lau, T. Pulinilkunnil, M. Allard, A. Abrahani, et al. Cardiac glycogen accumulation after dexamethasone is regulated by AMPK Am J Physiol Heart Circ Physiol, October 1, 2008; 295(4): H1753 - H1762. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Hammer, M. Snel, H. J. Lamb, I. M. Jazet, R. W. van der Meer, H. Pijl, E. A. Meinders, J. A. Romijn, A. de Roos, and J. W.A. Smit Prolonged Caloric Restriction in Obese Patients With Type 2 Diabetes Mellitus Decreases Myocardial Triglyceride Content and Improves Myocardial Function J. Am. Coll. Cardiol., September 16, 2008; 52(12): 1006 - 1012. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Hammer, R. W. van der Meer, H. J. Lamb, H. H. de Boer, J. J. Bax, A. de Roos, J. A. Romijn, and J. W. A. Smit Short-term flexibility of myocardial triglycerides and diastolic function in patients with type 2 diabetes mellitus Am J Physiol Endocrinol Metab, September 1, 2008; 295(3): E714 - E718. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Marfella, M. Barbieri, and G. Paolisso Insulin Therapy and Lipid Overload in Type 2 Diabetes JAMA, August 20, 2008; 300(7): 789 - 789. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Harmancey, C. R. Wilson, and H. Taegtmeyer Adaptation and Maladaptation of the Heart in Obesity Hypertension, August 1, 2008; 52(2): 181 - 187. [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Chess and W. C. Stanley Role of diet and fuel overabundance in the development and progression of heart failure Cardiovasc Res, July 15, 2008; 79(2): 269 - 278. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. W. van der Meer, S. Hammer, H. J. Lamb, M. Frolich, M. Diamant, L. J. Rijzewijk, A. de Roos, J. A. Romijn, and J. W. A. Smit Effects of Short-Term High-Fat, High-Energy Diet on Hepatic and Myocardial Triglyceride Content in Healthy Men J. Clin. Endocrinol. Metab., July 1, 2008; 93(7): 2702 - 2708. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. W. van der Meer, L. J. Rijzewijk, M. Diamant, S. Hammer, M. Schar, J. J. Bax, J. W.A. Smit, J. A. Romijn, A. de Roos, and H. J. Lamb The ageing male heart: myocardial triglyceride content as independent predictor of diastolic function Eur. Heart J., June 2, 2008; 29(12): 1516 - 1522. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. H. Opie Metabolic Management of Acute Myocardial Infarction Comes to the Fore and Extends Beyond Control of Hyperglycemia Circulation, April 29, 2008; 117(17): 2172 - 2177. [Full Text] [PDF]
|
|
|
|
 |
|
 J.-a Kim, Y. Wei, and J. R. Sowers Role of Mitochondrial Dysfunction in Insulin Resistance Circ. Res., February 29, 2008; 102(4): 401 - 414. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Fat Infiltrates Heart Before Diabetes Onset DOC News, November 1, 2007; 4(11): 15 - 15. [Full Text]
|
|
|
|
|
|
L. S. Szczepaniak, R. G. Victor, L. Orci, and R. H. Unger Forgotten but Not Gone: The Rediscovery of Fatty Heart, the Most Common Unrecognized Disease in America Circ. Res., October 12, 2007; 101(8): 759 - 767. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. L. Ruberg Myocardial Lipid Accumulation in the Diabetic Heart Circulation, September 4, 2007; 116(10): 1110 - 1112. [Full Text] [PDF]
|
|